Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170319 | 0.83 | KDM5A (0.41) | PAOXALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL2178380 | 0.82 | PAOX (0.53) | PAOXALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL10170627 | 0.82 | ALDH1A1 (0.35) | PAOXALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL10170634 | 0.78 | HPGD (0.34) | PAOXALDH1A1TSHRCHRM1CHRM2 | |
| Iodomethane SCHEMBL11880494 | 0.78 | PAOX (0.50) | PAOXALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL27266003 | 0.76 | PAOX (0.44) | PAOXALDH1A1TSHRCHRM1CHRM2 | |
| SCHEMBL10170633 | 0.74 | ALDH1A1 (0.39) | PAOXALDH1A1MEN1KMT2ACHRM1 | |
| SCHEMBL13290836 | 0.74 | ALDH1A1 (0.56) | PAOXALDH1A1CHRM1LMNASLC15A2 | |
| SCHEMBL14504379 | 0.73 | CYP1A2 (0.43) | ALDH1A1 | |
| SCHEMBL10247121 | 0.72 | CA12 (0.37) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | PAOX 1618/4885ALDH1A1 510/4885MEN1 1228/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | PAOX 1618/4885ALDH1A1 510/4885MEN1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.